Core Insights - Yangzheng Xiaojie Capsule is an innovative traditional Chinese medicine developed under the guidance of traditional Chinese medicine theory, targeting the pathological mechanisms of tumors and has been approved for use in primary liver cancer treatment in China [1][2] Group 1: Product Efficacy - Yangzheng Xiaojie Capsule integrates traditional methods with modern anti-cancer drugs, demonstrating a dual action of supporting the body while eliminating pathogens, which aligns with modern cancer treatment goals [1] - Clinical studies indicate that Yangzheng Xiaojie Capsule significantly improves the quality of life for patients with advanced non-small cell lung cancer, with a clinical symptom improvement rate of 83.5% [2] - In a study on primary liver cancer, the combination of Yangzheng Xiaojie Capsule with interventional chemotherapy resulted in a total effective rate of 65.2%, significantly higher than the control group's 36.1% [2] Group 2: Research and Validation - Research led by Professor Jiang Wenguo from Cardiff University found that Yangzheng Xiaojie Capsule can significantly interfere with tumor cell invasion and metastasis by inhibiting the excessive activation of the PI3K/AKT signaling pathway [1] - The same research also indicated that the capsule inhibits the activity of focal adhesion kinase, thereby suppressing tumor angiogenesis, which contributes to tumor starvation [1] Group 3: Market Expansion - Yangzheng Xiaojie Capsule has recently been approved in Thailand, marking a significant milestone in Yiling Pharmaceutical's internationalization strategy and demonstrating the practical application of traditional Chinese medicine in the "Belt and Road" initiative [4] - Yiling Pharmaceutical has successfully registered 17 innovative traditional Chinese medicines in over 50 countries and regions worldwide, indicating strong international market recognition [4]

Core Viewpoint - Yiling Pharmaceutical's stock has shown a significant increase this year, with a year-to-date rise of 24.44%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported a revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%. However, the net profit attributable to shareholders reached 1 billion yuan, reflecting a substantial year-on-year growth of 80.33% [2]. Stock Market Activity - As of November 26, Yiling Pharmaceutical's stock price was 19.55 yuan per share, with a trading volume of 4.24 billion yuan and a market capitalization of 32.662 billion yuan. The stock has experienced a 3.66% increase over the past five trading days and a 20.83% increase over the past 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 64.05 million yuan on January 6, contributing to a total buy of 233 million yuan, which accounted for 14.28% of total trading volume [1]. Shareholder Information - As of September 30, 2025, Yiling Pharmaceutical had 152,700 shareholders, a decrease of 10.22% from the previous period. The average number of circulating shares per shareholder increased by 11.38% to 9,013 shares [2]. - The company has distributed a total of 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited is the third-largest shareholder with 25.704 million shares, an increase of 8.1119 million shares from the previous period. Meanwhile, the Southern CSI 500 ETF has reduced its holdings by 256,900 shares [3].

Core Insights - The 2025 Yangtze River Delta Health Conference aims to promote high-quality development in health and wellness in the region, aligning with national strategies for "Healthy China" and regional integration [1][2][3] Group 1: Conference Overview - The conference is themed "Co-construction and Sharing, Inheritance and Innovation," focusing on collaborative health development and the promotion of traditional Chinese medicine (TCM) [1][2] - The event is organized by various health and media organizations, highlighting the importance of TCM as a unique health resource and economic asset [1][2] Group 2: Keynote Addresses and Insights - Notable speakers, including Chinese Academy of Engineering member Zhang Boli, emphasized the significance of TCM in modern health services and its role in achieving a "Healthy China" [2][3] - The conference highlighted the need for institutional alignment in regional cooperation and the integration of TCM into modern health systems [3] Group 3: Innovation and Collaboration - The conference facilitated the signing of several key TCM research projects, marking a significant step in translating research into clinical applications [4] - A collaborative mechanism for the inheritance of traditional TCM skills was established, aiming to integrate resources and cultivate talent in the region [4] Group 4: Publications and Academic Exchange - The launch of the book "The Health Code in Medicinal Paste" aims to make TCM knowledge accessible to the public, promoting understanding and benefits of TCM practices [5] - The conference also initiated the 2025 Jiangsu Province TCM Academic Annual Conference, fostering further academic exchange [5] Group 5: Industry Participation and Innovations - The event showcased a diverse range of industry leaders and innovations, including companies like Kangyuan Pharmaceutical and Huazhong Sanjiu, highlighting a complete industry chain from drug development to specialized medical foods [7] - The conference featured a technology transfer area where innovative TCM products were presented, demonstrating the transition from traditional remedies to modern healthcare solutions [7]

Core Insights - The article highlights the successful global registration and commercialization of 17 innovative traditional Chinese medicine (TCM) products by Yiling Pharmaceutical, marking a significant step in the internationalization of TCM [1][5][6] - Yiling Pharmaceutical has established a clear pathway for TCM's global integration, moving from physical expansion to cultural integration and value leadership [1][5] Group 1: Global Expansion of TCM - Yiling Pharmaceutical has successfully registered its innovative TCM products in over 50 countries and regions, demonstrating the global reach of Chinese medicine [1][5] - The company emphasizes the importance of theoretical foundations in TCM's internationalization, having developed a comprehensive theory system around "Luo disease" over 33 years [5][6] - The establishment of various international academic exchange platforms has facilitated the global dissemination and research of Luo disease theory [6][9] Group 2: Cultural Integration and Market Strategies - Yiling Pharmaceutical adopts a differentiated market strategy, tailoring its approach to meet the specific medical needs and cultural contexts of different regions [7][8] - In developed countries, the focus is on high-level clinical research to gain trust from the academic and regulatory communities, while in emerging markets, the company integrates its products into local healthcare systems [7][8] - The successful inclusion of Tongxinluo capsules in Vietnam's healthcare system exemplifies the company's effective local integration strategy [7] Group 3: Evidence-Based Medicine and Research - Yiling Pharmaceutical leads in evidence-based research, establishing a robust research framework that supports the clinical efficacy of its TCM products [9][10] - The company has conducted over 40 high-quality evidence-based studies on its innovative TCM products, with significant findings published in prestigious international medical journals [10][12] - This research not only validates the safety and efficacy of TCM but also presents its benefits in modern scientific language, enhancing its global acceptance [10][12] Group 4: Future Outlook and Challenges - Despite the progress, Yiling Pharmaceutical acknowledges ongoing challenges in cultural recognition and regulatory policies, particularly in non-Belt and Road countries [12] - The company believes that collaboration among government, industry, academia, and research institutions is essential to overcome these barriers and further the global impact of TCM [12]

在近期发布的中共中央关于"十五五"规划的建议中，"推进中医药传承创新，促进中西医结合"再度被提 及。近年来，中医药作为"民族瑰宝"不仅需要传承，更需要与时俱进推动创新，走向全球，已逐渐成为 越来越多业界人士的共识。 众多上市公司中，专利中药龙头公司以岭药业（002603.SZ）正是中医药现代化的践行者。近日，以岭 医药研究院副院长、中药研究院院长魏聪及以岭药业国际贸易中心负责人孙学非接受媒体采访，阐述了 以岭药业在中医药现代化及国际化层面的贡献。 孙学非介绍，在东南亚市场，通心络胶囊等通络中药以药品身份进入医保目录；而在东欧某些国家，受 限于当地法规，只能以保健品类别销售。针对这种情况，企业采取"本土化适配"策略：在越南，联合当 地医院开展临床观察；在非洲，与传统医学机构合作进行药物特性研究。孙学非回忆，这种"入乡随 俗"的严谨态度，让通心络胶囊成为该国首批以"草药与天然药物"身份获批进入医院销售的中国中成 药。 "如今，在加拿大温哥华的连锁药房、肯尼亚内罗毕的中医诊所，以岭药业的产品已不再是陌生面孔。 更值得关注的是，其自主研发的酸枣仁油软胶囊获得百余个国际批文。"孙学非表示，这种转变背后， 是中医药从"文 ...

消息面上，11月以来，全国流感活动快速上升，北京已迈入呼吸道传染病高发期。有数据显示，奥司他 韦近7天销量暴涨237%，速福达（玛巴洛沙韦）涨幅达180%，美团买药平台数据更显示，11月以来北 京甲乙流特效药环比增长超130%，其中速福达增长超110%，磷酸奥司他韦颗粒增长超85%。另据阿里 健康平台数据，近两周（11月10日—11月23日）流感应季药品的关注度和购买量均有明显提升，其中流 感抗病毒药物购买人数呈现超500%的环比增长。 机构表示，近期流感活动度持续攀升，当前已攀升至近2022年以来同期高位，流感用药需求增加，关注 流感高发带来的呼吸系统用药需求增长。 生物疫苗概念25日盘中震荡走高，截至发稿，金迪克20%涨停，华兰疫苗涨超10%，海南海药亦涨停， 一品红涨超9%，以岭药业涨逾5%。 ...

Core Viewpoint - The article emphasizes the importance of traditional Chinese medicine (TCM) internationalization through theoretical foundations, scientific innovation, and cultural integration, highlighting Yiling Pharmaceutical's efforts in promoting TCM globally [5][7][9]. Group 1: Theoretical Foundation and Academic Development - Yiling Pharmaceutical has established a comprehensive theoretical framework for "Luo Disease" over 33 years, which is considered a significant milestone in TCM development [5]. - The company has published several authoritative texts on Luo Disease, including "Luo Disease Studies" and "Meridian Theory," which are used in international educational institutions to train TCM professionals [5][6]. - Yiling has created multiple academic exchange platforms globally, including various international associations and conferences, to promote the study and dissemination of Luo Disease theory [6]. Group 2: Market Strategies and Cultural Integration - The company adopts a differentiated market strategy, "one country, one policy," to align with the medical needs and cultural contexts of different regions [7]. - In developed countries, Yiling focuses on high-level clinical research to gain trust from the academic and regulatory communities, while in emerging markets, it integrates products into local healthcare systems [7]. - The successful inclusion of Tongxinluo capsules in Vietnam's medical insurance directory exemplifies the company's effective local integration [7]. Group 3: Evidence-Based Research and International Recognition - Yiling Pharmaceutical has pioneered evidence-based research in TCM since 1995, establishing a robust research system and innovation platform [9][10]. - The company has conducted over 40 high-quality evidence-based studies on its 17 innovative TCM products, with significant findings published in prestigious international medical journals [9][10]. - These studies validate the efficacy and safety of TCM, presenting its wisdom in modern scientific language, thus facilitating international recognition [10]. Group 4: Future Outlook and Challenges - Yiling Pharmaceutical acknowledges the challenges of cultural recognition and regulatory policies in non-Belt and Road countries for TCM's international expansion [12]. - The company believes that collaboration among government, industry, academia, and research institutions is essential to overcome these barriers [12]. - There is confidence that by balancing tradition and innovation, TCM can contribute significantly to global health governance [12].

Group 1 - The core viewpoint of the news highlights the strong performance of the Traditional Chinese Medicine (TCM) sector, driven by supportive government policies aimed at innovation and industrial transformation [1][2] - The Shanghai government has issued a document encouraging collaboration among medical institutions, research units, and pharmaceutical companies to create platforms for TCM innovation and industrial transformation [1] - The document supports the development of major TCM varieties and the secondary development of classic varieties, as well as the establishment of mechanisms for collecting and organizing human experience data for drug registration [1] Group 2 - China Galaxy Securities anticipates that policy-driven changes will continue to propel the pharmaceutical industry towards innovation and upgrades, with a focus on finding incremental opportunities in niche markets [2] - The report indicates that domestic innovative drugs are expected to yield results, with several second-generation I/O drugs and ADCs entering phase three clinical trials, which is promising for future developments [2] - The TCM prescription drug market is facing clinical re-evaluation, which may reshape the market landscape and potentially lead to a turning point in TCM gross margins [2] Group 3 - The TCM ETF closely tracks the Zhongzheng TCM Index, which selects listed companies involved in TCM production and sales to reflect the overall performance of TCM concept stocks [2] - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng TCM Index account for 54.92% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Core Insights - The fifth Huaxia Health Industry Development and Rehabilitation Service Conference was held in Beijing, where Yiling Pharmaceutical was recognized for its achievements in traditional Chinese medicine innovation, being selected as a "2025 Annual Traditional Chinese Medicine Innovation Model Case" [1] Group 1: R&D Investment and Achievements - Yiling Pharmaceutical prioritizes R&D as the core driver of its development, with R&D investment reaching 544 million yuan in the first three quarters of 2025, accounting for 9.27% of its operating revenue, leading the industry [3] - Cumulatively, from 2019 to 2024, the company has invested over 5 billion yuan in R&D, establishing a virtuous cycle of "investment-transformation-reinvestment" to produce "Chinese medicine" that aligns with the genetic and physical characteristics of the Chinese population [3] - In 2025, Yiling Pharmaceutical's R&D pipeline has yielded significant results, including the approval of the traditional Chinese medicine Qifang Nasal Congestion Tablets by the National Medical Products Administration, which has also been registered in Macau, marking it as the first registered innovative traditional Chinese medicine in Macau [3] Group 2: Product Development and Market Impact - Four new traditional Chinese medicines, including Qigui Luobitong Tablets and Children's Lianhua Qingwen Granules, are in the application stage, while five others are undergoing clinical research, covering major diseases in respiratory, rheumatology, and neurology fields [3] - Yiling Pharmaceutical holds 17 patented traditional Chinese medicines that address major diseases such as cardiovascular, respiratory, and endocrine disorders, with 11 products included in the national medical insurance catalog and five in the national essential drug catalog, effectively reducing the medication burden on patients [3] Group 3: Evidence-Based Medicine and Global Outreach - The company emphasizes high-standard evidence-based medical research to promote traditional Chinese medicine globally, with its series of studies on vascular event chain interventions attracting international attention, published in top medical journals such as JAMA and Nature Medicine [4] - Yiling Pharmaceutical has initiated over 40 evidence-based medical studies, establishing a research evidence system that integrates traditional Chinese and Western medicine [4] Group 4: Industry Recognition and Innovation - The selection process for the innovation model cases involved extensive research and professional evaluation by hundreds of media outlets, experts, and industry scholars, highlighting representative and exemplary innovation cases across various dimensions, including corporate practices, technology applications, brand building, and cultural stories [4][5] - The release and display of these cases aim to convey a positive industry trend, promote a pragmatic and innovative spirit, and foster the healthy development of enterprises in the health sector [5]

Summary of Yiling Pharmaceutical Conference Call Company Overview - Yiling Pharmaceutical was established in 1992, focusing on the research, production, and sales of patented traditional Chinese medicine (TCM) [3][4] - The company has developed a synergistic industrial structure comprising patented TCM, chemical drugs, and health industries [2][3] Core Business Segments Cardiovascular Products - The cardiovascular product line includes Tongxinluo, Shensongyangxin, and Qiyiliqiangxin capsules, targeting ischemic cardiovascular diseases, arrhythmias, and heart failure [2][6] - These products have shown clinical efficacy through evidence-based medicine and have maintained a leading market share from 2017 to 2024 [6] - Shensongyangxin and Tongxinluo capsules consistently rank at the forefront of the market, while Qiyiliqiangxin has improved from 16th to 6th place [6] Respiratory Products - The respiratory product line features Lianhua Qingwen, Lianhua Qingke, and Qifang Bitong tablets [2][7] - Lianhua Qingwen significantly contributed to revenue during the pandemic from 2020 to 2022, and demand is expected to rebound in 2025 due to an increase in flu cases [7] - Lianhua Qingke transitioned to an OTC product in 2023, and Qifang Bitong tablets are anticipated to provide additional growth [7] Secondary Products - Secondary products include Bazibu Shen capsules, Jiyu Chufan capsules, and Yishen Yangxin Anshen tablets, targeting anti-aging, depression, and insomnia [2][8][9] - These products are promoted through retail and e-commerce channels, aiming for a breakout effect [10] Innovation and Regulatory Approvals - The company’s innovative TCM, Tongluoming Maimu capsules, was approved for diabetes retinopathy treatment and included in the 2024 edition of the Chinese Diabetes Prevention and Treatment Guidelines [2][11] - Yiling has 17 patented TCM products and several innovative drugs in development, with three 1.1 class new drugs in the application stage [12] Chemical Drug Sector - The chemical drug segment has achieved 15 ANDA products approved by the FDA and 13 products passing domestic consistency evaluations [5][13] - The company is focusing on innovative drug development, with several products in clinical trials, including Benlufen injection for postoperative pain [13] Health Industry Development - The health segment has established five core product series, including health drinks and sleep aids, which have performed well on e-commerce platforms [5][14][15] - These products cater to workplace elites, the elderly, and family health management needs [15] Future Growth Drivers - Key factors expected to drive future growth include: 1. Continued market share increase in core cardiovascular and respiratory products [10] 2. Gradual market penetration of new products like Lianhua Qingke and Qifang Bitong [10] 3. Promotion of secondary products through retail and e-commerce [10] 4. Ongoing evidence-based research to enhance clinical promotion [10] 5. Expansion of the anti-aging market and shifts in consumer health spending [10] Financial Projections - Projected revenues for 2025, 2026, and 2027 are 8.2 billion, 9.1 billion, and 10.1 billion CNY, representing year-on-year growth of 27%, 11%, and 10% respectively [16] - Significant recovery in net profit is expected in 2025, with growth rates in 2026 and 2027 anticipated to exceed revenue growth [16] Additional Considerations - Potential catalysts for future growth include the introduction of new basic drug management regulations, adjustments to the basic drug catalog, and the upcoming approval of the chemical new drug Benlufen injection [16] - An increase in flu-like cases may also boost demand for respiratory products like Lianhua Qingwen [16]